Press Releases



 
Press Releases
  Date Title View
May 10, 2017
REDWOOD CITY, Calif., May 10, 2017 /PRNewswire/ -- Genomic Health, Inc. (Nasdaq: GHDX) today announced that it will present at the Bank of America Merrill Lynch 2017 Health Care Conference in Las Vegas on Wednesday, May 17, 2017 at 11:20 a.m. Pacific Time. To access the live and subsequently archived webcast of the presentation, go to the In...
PDF
May 9, 2017
REDWOOD CITY, Calif., May 9, 2017 /PRNewswire/ -- Genomic Health, Inc. (Nasdaq: GHDX) today reported financial results and business progress for the quarter ended March 31, 2017. Total revenue was $84.0 million in the first quarter of 2017, compared with $80.9 million in the first quarter of 2016, an increase of 4 percent. U.S. produ...
PDF
May 4, 2017
REDWOOD CITY, Calif., May 4, 2017 /PRNewswire/ -- Genomic Health, Inc. (Nasdaq: GHDX) today announced that Palmetto GBA, a Medicare Administrative Contractor (MAC) that assesses molecular diagnostic technologies, has issued a draft local coverage determination (LCD) for the Oncotype DX® Genomic Prostate Score™ (GPS). The draft LCD recomm...
PDF
May 4, 2017
REDWOOD CITY, Calif., May 4, 2017 /PRNewswire/ -- Genomic Health, Inc. (Nasdaq: GHDX) today announced that results from four new Oncotype DX® Genomic Prostate Score™ (GPS) studies will be presented at the upcoming American Urological Association (AUA) 2017 Annual Meeting, which will be held May 12-16 in Boston. With new results reporting...
PDF
May 2, 2017
REDWOOD CITY, Calif., May 2, 2017 /PRNewswire/ -- Genomic Health, Inc. (NASDAQ: GHDX) today announced that the company will host a conference call and webcast on Tuesday, May 9 at 4:30 p.m. Eastern Time to discuss its first quarter 2017 financial results.  The call and webcast will follow the release of the first quarter financial results after mar...
PDF
Mar 29, 2017
REDWOOD CITY, Calif., March 29, 2017 /PRNewswire/ -- Genomic Health, Inc. (Nasdaq: GHDX) today announced the presentation of new results from a large multi-center validation study, which confirmed that the Oncotype DX® Genomic Prostate Score™ (GPS) is a strong independent predictor of metastases at 10 years in prostate cancer patients ac...
PDF
Mar 24, 2017
REDWOOD CITY, Calif., March 24, 2017 /PRNewswire/ -- Genomic Health, Inc. (Nasdaq: GHDX) today announced the publication of results from the National Cancer Institute's (NCI) Surveillance, Epidemiology, and End Results (SEER) Registry in the peer-reviewed journal Breast Cancer Research and Treatment, reconfirming the value of the Oncotype DX Breast...
PDF
Mar 20, 2017
REDWOOD CITY, Calif., March 20, 2017 /PRNewswire/ -- Genomic Health, Inc. (Nasdaq: GHDX) today announced results from 15 Oncotype DX Breast Recurrence Score® studies conducted in 12 countries that provide real-world evidence of the test's ability to change treatment decisions in breast cancer patients. The new findings, presented at the 15th S...
PDF
Feb 28, 2017
REDWOOD CITY, Calif., Feb. 28, 2017 /PRNewswire/ -- Genomic Health, Inc. (NASDAQ: GHDX) today announced that Kim Popovits, chairman of the board, chief executive officer and president, will present at the Cowen and Company 37th Annual Health Care Conference at the Marriot Copley Place in Boston on Tuesday, March 7, 2017 at 11:20 a.m. Eastern Time. ...
PDF
Feb 16, 2017
REDWOOD CITY, Calif., Feb. 16, 2017 /PRNewswire/ -- Genomic Health, Inc. (NASDAQ: GHDX) announced today the presentation of results from four studies evaluating the clinical value and utility of its Oncotype DX® Genomic Prostate Score™ (GPS) in the management of early-stage prostate cancer. Collectively, these new data highlight the test...
PDF
FirstPrevious
3
...
NextLast